Amarex Submits IND Application for Treatment of a Rare Pediatric Disorder
Germantown, MD, USA (May 26, 2020) – On May 21, 2020, Amarex Clinical Research, LLC, an NSF International company, on behalf of a client, submitted an Investigational New Drug (IND) application for a therapeutic treatment of a rare, debilitating genetic disease that affects the quality of life and life span of children.
Dr. Kazem Kazempour, Amarex President & CEO, stated, “While Amarex is heavily involved with the COVID-19 response efforts, we continue to work diligently on clients’ projects that are non-COVID related. This project, in particular, is a good example of a dire need for the children affected. There is no treatment for this terrible disease and we are grateful to be part of the product development effort that may provide some relief to the youngest of patients.”
About Amarex Clinical Research, LLC, an NSF International company
Amarex Clinical Research, LLC, an NSF International company, is a global, full-service Contract Research Organization (CRO), whose leadership team has significant expertise conducting biomedical research, and whose combined experience includes the design and conduct of several hundred clinical research projects in many therapeutic indications. Amarex provides comprehensive services in Project Management (Phase I-IV, BE/BA, PK/PD), Regulatory Affairs (FDA Applications and meetings, Applications to International Health Authorities, GxP Compliance Audits), Clinical Operations, Adaptive Study Designs, Statistical Analysis, Data Management, Medical Monitoring, Safety and Pharmacovigilance, and General Consulting. Amarex can take your product through the entire approval process, from creating the regulatory approval strategy, to conducting trials, to writing the marketing approval application. Join our growing list of clients with approved products. Amarex provides high quality and cost-efficient services. For more information visit www.amarexus.com.
Book a meeting or send us a message to talk to one of our experts.